

AWAL MAIL BERITA KEUANGAN OLAHRAGA SELEB LIFESTYLE LAINNYA..

Tingkatkan Sekarang

editorial@f1000research...    ▼



Awal

Tulis

Kembali        ...

26

Email Masuk

Belum Dibaca

Berbintang

Draft

Terkirim

Arsip

Spam

Sampah

Lebih sedikit

Tampilan Sembunyikan

Foto

Dokumen

Langganan

Folder Sembunyikan

Folder Baru

Deleted Items

Notes

Sent Items

Your article has been submitted 110686

Yahoo/Email M... ☆



editorial@f1000research.com  
Kepada: erwintriyono@yahoo.com

Kam, 10 Mar 2022 jam 12.10 ☆

Dear Erwin

Fenska Seipalla has submitted this manuscript:

**Clinical Characteristics of Patients with COVID-19 Admitted to the COVID-19 Emergency Field Hospital of Bangkalan, Indonesia**

Erwin Triyono *et al.* with Fenska Seipalla as the corresponding author(s).

**Funders:** no grant funding was stated during submission.

**Before accepting the article:** we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).

**Before publishing the article:** if we accept the article, we will be in touch with Fenska Seipalla as soon as possible with any issues that need addressing and ask them for reviewer suggestions. They will then receive a final proof of the article for approval, prior to publication. At that stage, the peer review process will begin, in accordance with our publishing model.

**After publication:** to ensure you receive proper recognition for your professional activities, you can connect your ORCID iD to F1000Research so that all your F1000Research work is added to your account automatically once it is published. Details on how to do this will be sent in an email when the article is published.

All future correspondence about this submission will be sent to Fenska Seipalla only. If you have not agreed to this submission and your inclusion as an author of this article, please contact us immediately quoting the article number: 110686.

Kind regards

The F1000Research Team

**Press releasing articles:** Please avoid promoting articles in the media until the article has passed the open peer review process. Promotion on social media is encouraged once the article has been

Your article has been submitted 110686

96

Dari: editorial@f1000research.com

Kepada: erwintriyono@yahoo.com

Tanggal: Kamis, 10 Maret 2022 12.10 WIB

Dear Erwin

Fenska Seipalla has submitted this manuscript:

**Clinical Characteristics of Patients with COVID-19 Admitted to the COVID-19 Emergency Field Hospital of Bangkalan, Indonesia**

Erwin Triyono *et al.* with Fenska Seipalla as the corresponding author(s).

**Funders:** no grant funding was stated during submission.

**Before accepting the article:** we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).

**Before publishing the article:** if we accept the article, we will be in touch with Fenska Seipalla as soon as possible with any issues that need addressing and ask them for reviewer suggestions. They will then receive a final proof of the article for approval, prior to publication. At that stage, the peer review process will begin, in accordance with our publishing model.

**After publication:** to ensure you receive proper recognition for your professional activities, you can connect your ORCID ID to F1000Research so that all your F1000Research work is added to your account automatically once it is published. Details on how to do this will be sent in an email when the article is published.

All future correspondence about this submission will be sent to Fenska Seipalla only. If you have not agreed to this submission and your inclusion as an author of this article, please contact us immediately quoting the article number: 110686.

Kind regards

The F1000Research Team

**Press releasing articles:** Please avoid promoting articles in the media until the article has passed the open peer review process. Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

Do not delete (filing code): F1KR00CDE F1R-VER122315-A (end code)

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Your article has been submitted 110716

Dari: editorial@f1000research.com

Kepada: erwintriyono@yahoo.com

Tanggal: Jumat, 11 Maret 2022 00.09 WIB

Dear Erwin

Fenska Seipalla has submitted this manuscript:

**Clinical Characteristics of Patients with COVID-19 Admitted to the COVID-19 Emergency Field Hospital of Bangkalan, Indonesia**

Erwin Triyono *et al.* with Erwin Triyono, Fenska Seipalla as the corresponding author(s).

**Funders:** no grant funding was stated during submission.

**Before accepting the article:** we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).

**Before publishing the article:** if we accept the article, we will be in touch with Fenska Seipalla as soon as possible with any issues that need addressing and ask them for reviewer suggestions. They will then receive a final proof of the article for approval, prior to publication. At that stage, the peer review process will begin, in accordance with our publishing model.

**After publication:** to ensure you receive proper recognition for your professional activities, you can connect **your ORCID ID** to F1000Research so that all your F1000Research work is added to your account automatically once it is published. Details on how to do this will be sent in an email when the article is published.

All future correspondence about this submission will be sent to Fenska Seipalla only. If you have not agreed to this submission and your inclusion as an author of this article, please contact us immediately quoting the article number: 110716.

Kind regards

The F1000Research Team

**Press releasing articles:** Please avoid promoting articles in the media until the article has passed the open peer review process. Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

Do not delete (filing code): F1KR00CDE F1R-VER122349-A (end code)

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.



8 96

## Article submission received

1 message

<editorial@f1000research.com>  
To: fenskaledge@gmail.com

Thu, Mar 10, 2022 at 12:10 PM

Dear Fenska

Thank you for submitting your manuscript:

### **Clinical Characteristics of Patients with COVID-19 Admitted to the COVID-19 Emergency Field Hospital of Bangkalan, Indonesia**

Triyono E *et al.*

**Funders:** no grant funding was stated during submission.

**Article Processing Charges (APCs) on F1000Research are based on article type. Charges are payable once the article has been accepted for publication. A full explanation of the price transparency breakdown for the article type categories is available [here](#).**

#### **WHAT WE DO NEXT**

**Before accepting your article:** we will check content suitability, readability and manuscript format; adherence to ethical standards for the type of study; that the underlying data have been supplied (where appropriate); and that there is sufficient detail to enable others to replicate the study (if applicable).

**Before publishing your article:** if we accept your article, we will be in touch as soon as possible with any issues that need addressing. You will then receive a final proof of your article for approval, prior to publication.

#### **WHAT YOU NEED TO DO NEXT**

Before doing anything else, we need you to suggest **at least 5** suitable reviewers to peer review your manuscript following publication (in accordance with our [publishing model](#)), should it be accepted. We ask that authors do not contact reviewers directly about the peer review process. We will need your reviewer suggestions before we can publish the article so we recommend identifying them now via your [Suggest Reviewers](#) page for this article. You can also access this page via the article's record at [My Research >> Submissions](#).

Please quote the article number 110686 in any correspondence.

Kind regards

The F1000Research Team

**Press releasing articles:** Please avoid promoting articles in the media until the article has passed the [open peer review process](#). Promotion on social media is encouraged once the article has been published; please ensure the full citation is included, as this contains the peer review status. F1000Research should be cited as the source of these articles with a link to the article.

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER122315-A (end code)



---

## Peer review report or update received

1 message

---

<editorial@f1000research.com>  
To: fenskaledge@gmail.com

Fri, Aug 26, 2022 at 6:17 PM

Dear Fenska

Clinical characteristics of patients with COVID-19 admitted to the COVID-19 Emergency Field Hospital of Bangkalan, Indonesia

Triyono EA, Seipalla F, Djaja N, Akbas AMI, Ar-Rahmah KA, Budiono PS, Pamungkas AP, Fernanda Y *et al.*

I'm writing to inform you that Zhongheng Zhang has reviewed version 2 of your article and has **maintained their status of Approved**. You can read their comments [here](#).

As a reminder, the definitions of the approval statuses awarded by reviewers are:

**Approved:** No or only minor changes are required.

**Approved with Reservations:** The reviewer has asked for a number of small changes to the article, or specific, sometimes more significant revisions.

**Not Approved:** Crucial substantial revisions will be required for the paper to pass peer review. It is important to note that a Not Approved status is not a rejection.

If you wish to respond directly to the reviewer by adding a comment to their report (now, or at a later stage), please click the 'Respond to this report' button below the peer review report. When responding to a peer review report, please try and make sure you are logged into the account that you originally used for the submission of this article, otherwise we cannot identify your response as being from an author. Please allow up to one working day for your comment to appear (comments explaining changes in the revised version of your article are usually published at the same time as the revised article).

Best regards,

Joe (on behalf of Olivia)  
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER137400-A (end code)



## Peer review report or update received

1 message

<editorial@f1000research.com>  
To: fenskaledge@gmail.com

Tue, Sep 20, 2022 at 5:53 PM

Dear Fenska,

Clinical characteristics of patients with COVID-19 admitted to the COVID-19 Emergency Field Hospital of Bangkalan, Indonesia

Triyono EA, Seipalla F, Djaja N, Akbas AMI, Ar-Rahmah KA, Budiono PS, Pamungkas AP, Fernanda Y *et al.*

I'm writing to inform you that Petrick Periyasamy has reviewed version 2 of your article and has **changed their previous status FROM 'Approved with Reservations' TO 'Approved'**. You can read their comments [here](#).

As your article has now received the required approval from the reviewers to be indexed, it should appear on PubMed, PMC, Scopus, Embase and other indexing sites within a few weeks.

Although your article has now passed peer review, you can still revise or update it at any point now or in the future. For information on how to submit a new version, please visit [Article Guidelines \(new versions\)](#). Please bear in mind that new submissions need to be created and submitted using the submitting author's account.

As a reminder, the definitions of the approval statuses awarded by reviewers are:

**Approved:** No or only minor changes are required.

**Approved with Reservations:** The reviewer has asked for a number of small changes to the article, or specific, sometimes more significant revisions.

**Not Approved:** Crucial substantial revisions will be required for the paper to pass peer review. It is important to note that a Not Approved status is not a rejection.

If you wish to respond directly to the reviewer by adding a comment to their report (now, or at a later stage), please click the 'Respond to this report' button below the peer review report. When responding to a peer review report, please try and make sure you are logged into the account that you originally used for the submission of this article, otherwise we cannot identify your response as being from an author. Please allow up to one working day for your comment to appear (comments explaining changes in the revised version of your article are usually published at the same time as the revised article).

Kind regards,

Olivia  
The Editorial Team, F1000Research

F1000Research is the trading name of F1000 Research Limited. This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender. F1000 Research Limited does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of F1000 Research Limited. No contracts may be concluded on behalf of F1000 Research Limited by means of e-mail communication. F1000 Research Limited is Registered in England and Wales with Company Number 8322928, Registered Office Howick Place, London SW1P 1WG, UK.

Do not delete (filing code): F1KR00CDE F1R-VER137400-A (end code)